Carcinoma, Non-Small-Cell Lung: all 6,645 studies

Page 33 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.

• Study of IK-595 in RAS- or RAF-altered Advanced TumorsTerminatedNCT06270082Phase 1
• A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based ChemotherapyActive, not recruitingNCT06268613Phase 1
• Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung CancerActive, not recruitingNCT06268210Phase 2
• A Study of KK2269 in Adult Participants With Solid TumorsActive, not recruitingNCT06266299Phase 1
• Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerActive, not recruitingNCT06253520Phase 1
• Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung CancerCompletedNCT06249854Phase 2
• Korean Registry of Non-Small Cell Lung Cancer Patients with EGFR MutationActive, not recruitingNCT06247280
• Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic AlterationsActive, not recruitingNCT06245837
• The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLCActive, not recruitingNCT06243679
• A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid TumorsActive, not recruitingNCT06238479Phase 1
• Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT06236438Phase 2/3
• GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung CancerTerminatedNCT06235242Not applicable
• PPIO-006 Primary Tumor Resection for IVa NSCLCCompletedNCT06232967
• Molecular Diagnosis of Lung Cancer Via Bronchoscopy: The Significance of Bronchial Liquid Biopsy (ctDNA and ctRNA)CompletedNCT06228508
• A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung CancerActive, not recruitingNCT06225804Phase 1
• Clinical Effectiveness of Combining Mindfulness-Based Stress Reduction With Exercise InterventioneCompletedNCT06224504Not applicable
• A Study to Learn How BAY2927088 is Taken up and Handled by the Body in Healthy Male ParticipantsCompletedNCT06221475Phase 1
• Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLCActive, not recruitingNCT06219317Phase 2
• Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)SuspendedNCT06219174Phase 1/2
• Role of Neutrophils and Electro-bioluminescence in the RehabilitationCompletedNCT06209229Phase 1
• BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid TumorsActive, not recruitingNCT06205706Phase 1/2
• A Study to Investigate the Family History of Cancer in Patients With Non-small Cell Lung Cancer (FAHIC - Lung).CompletedNCT06196424
• Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS ≥ 50%: a Prospective, Single-center, Single-arm Phase 2 Study.Active, not recruitingNCT06195683Phase 2
• Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILDTerminatedNCT06192004
• --SuPERIOR Trial--TerminatedNCT06191250Phase 2
• S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAPActive, not recruitingNCT06188702Phase 1/2
• A Study to Investigate Safety, Tolerability, PK and Anti-tumor Activity of TRX-221 in EGFRm NSCLC PatientsTerminatedNCT06186076Phase 1/2
• Segmentectomy vs LobectomyActive, not recruitingNCT06180239
• Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLCTerminatedNCT06173505Phase 1/2
• PRO1107 in Patients With Advanced Solid TumorsTerminatedNCT06171789Phase 1/2
• Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT06162572Phase 1/2
• A Study of Lymph Node Metastatic Pattern Based Incorporating Tumor Location, GGO Components and Size for Non-small Cell Lung CancerCompletedNCT06161935
• Treatment Patterns and Real-World Clinical Outcomes in Patients With Advanced NSCLC and MET Exon 14 Skipping Mutation in the United StatesCompletedNCT06161051
• A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)CompletedNCT06159790Phase 3
• A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid TumorsTerminatedNCT06158958Phase 1
• A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid TumoursActive, not recruitingNCT06147037Phase 1
• Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment DiscontinuationActive, not recruitingNCT06146920Not applicable
• A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)Active, not recruitingNCT06140836Phase 3
• The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLCCompletedNCT06139419Phase 2
• Expanded Access Use of Cemiplimab in Patients With Solid TumorsApproved for marketingNCT06132191
• A Study of AMG 355 Alone and in Combination With Pembrolizumab in Participants With Advanced Solid TumorsCompletedNCT06131398Phase 1
• Tumor Treating Fields for Locally Advanced NSCLCWithdrawnNCT06124118Phase 1
• Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus LazertinibActive, not recruitingNCT06120140Phase 2
• A Study of AB801 Monotherapy and Combination Therapy in Participants With Advanced MalignanciesCompletedNCT06120075Phase 1
• A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung CancerActive, not recruitingNCT06116786Phase 1
• A Study of BL-M07D1 in Patients With HER2-Overexpressing or HER2-Mutant Locally Advanced or Metastatic Non-Small Cell Lung CancerActive, not recruitingNCT06114511Phase 1/2
• Study of DF6215 in Patients With Advanced Solid TumorsCompletedNCT06108479Phase 1
• Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid TumorActive, not recruitingNCT06105021Phase 1/2
• Medical Access Program for Patritumab DeruxtecanNo longer availableNCT06099639
• Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met ProteinWithdrawnNCT06093503Phase 3
• Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT06091943Phase 1
• Targeting MDMD and PD1 in Tumors With Tertiary Lymphoid StructuresWithdrawnNCT06084689Phase 2
• PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung CancerActive, not recruitingNCT06083857Phase 1/2
• Ascorbate With Durvalumab in Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT06083454Phase 1
• TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT06082635Phase 3
• A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)Active, not recruitingNCT06077760Phase 3
• A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.WithdrawnNCT06075615
• Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)Active, not recruitingNCT06074588Phase 3
• A Study to Assess Prevalence of a Specific Protein Overexpression in Adult Participants With Non-Small Cell Lung CancerCompletedNCT06068842
• AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLCWithdrawnNCT06068153Phase 2
• Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLCWithdrawnNCT06064279Phase 1/2
• CX3CR1+T Cell Predict Immunotherapy EfficacyCompletedNCT06054152
• Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced MalignanciesTerminatedNCT06052852Phase 1
• Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)Active, not recruitingNCT06049212Phase 1
• A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC RegionCompletedNCT06039683
• BBP-398 in Combination With Osimertinib in Locally Advanced or Metastatic NSCLC Patients With EGFR MutationsTerminatedNCT06032936Phase 1
• Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLCActive, not recruitingNCT06031558Phase 3
• Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)TerminatedNCT06022757Phase 1/2
• SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKIActive, not recruitingNCT06020066Phase 2
• Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.Status unknownNCT06018688Phase 2
• The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRTCompletedNCT06015815
• Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung CancerActive, not recruitingNCT06015724Phase 2
• A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC)Active, not recruitingNCT06015503Phase 2
• Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung CarcinomaSuspendedNCT06014827Phase 2
• A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung CancerActive, not recruitingNCT06012435Phase 3
• A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRASActive, not recruitingNCT06008093Phase 2
• A Study of Lorlatinib in Combination With Ramucirumab in People With Lung CancerActive, not recruitingNCT06007937Phase 1/2
• A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2Active, not recruitingNCT06003231Phase 2
• Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLCCompletedNCT06001671Phase 1
• Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) NegativeActive, not recruitingNCT06001151Phase 2
• JDQ443 for KRAS G12C NSCLC Brain MetastasesWithdrawnNCT05999357Phase 2
• A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.Active, not recruitingNCT05984277Phase 3
• A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid TumorsTerminatedNCT05983133Phase 1
• Clinicopathological Characteristics and Prognosis Analysis of Stage IB Non-small Cell Lung CancerCompletedNCT05979623
• REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)Active, not recruitingNCT05973773Phase 3
• PET-CT Predicting Lymph Nodes MetastasisActive, not recruitingNCT05970913
• A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7SuspendedNCT05958199Phase 1
• Breathe Easier II: A Dyad-based Multiple Behavior InterventionCompletedNCT05956782Not applicable
• TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05955391Phase 2
• Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal CancerCompletedNCT05954871Phase 1
• A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid TumorsActive, not recruitingNCT05949619Phase 1/2
• A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung CancerActive, not recruitingNCT05949606Phase 1/2
• Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent LorlatinibWithdrawnNCT05948462Phase 2
• A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingNCT05941897Phase 2
• Metabolic Response to Food in Lung CancerTerminatedNCT05937074
• OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung CancerWithdrawnNCT05935774Phase 2
• RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in CanadaCompletedNCT05933044
• Integrative Multi-Omics Testing for Immunotherapy Response in Non-Small Cell Lung CancerCompletedNCT05928299
• Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)CompletedNCT05926180Phase 1
• Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)Active, not recruitingNCT05925530Phase 2

← Carcinoma, Non-Small-Cell Lung overview